Beth C. Seidenberg - Sep 18, 2024 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
Sep 18, 2024
Transactions value $
-$696,233
Form type
4
Date filed
9/20/2024, 04:45 PM
Previous filing
Jun 11, 2024
Next filing
Oct 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Sale -$49.4K -1.18K -0.73% $42.01 160K Sep 18, 2024 Direct F1, F2, F3, F4
transaction VERA Class A Common Stock Sale -$62K -1.48K -26.9% $42.00 4.01K Sep 18, 2024 See Footnote F1, F5, F6
transaction VERA Class A Common Stock Sale -$585K -13.8K -8.62% $42.31 147K Sep 19, 2024 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 19, 2024.
F2 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.07, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 In prior reports, the Reporting Person reported indirect beneficial ownership of 1,949,295 shares of Class A Common Stock (the "Shares") held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and KPCB XVI Founders Fund, LLC ("XVI Founders"), whose managing member is KPCB XVI Associates, LLC ("XVI Associates"). On April 10, 2024, KPCB XVI and XVI Founders made a pro-rata in-kind distribution of 750,000 Shares without consideration to its members, including XVI Associates, and likewise on June 5, 2024, they made an additional pro-rata in-kind distribution of 1,199,295 Shares to its members, including XVI Associates.
F4 On April 10, 2024, April 12, 2024, June 5, 2024 and June 13, 2024, the Reporting Person received an aggregate of 161,553 Shares as part of a pro-rata in-kind distribution without consideration from KPCB XVI, XVI Founders and their managing member, XVI Associates. The Reporting Person is one of the five managing members of XVI Associates.
F5 On April 10, 2024 and June 5, 2024, an aggregate of 5,488 Shares were received as part of a pro-rata in-kind distribution without consideration from XVI Associates, the managing member of KPCB XVI and XVI Founders. The Reporting Person is one of the five managing members of XVI Associates.
F6 Shares are held by the Samuel B. Seidenberg Irrevocable Trust, established on July 1, 2013, for which the Reporting Person and her spouse serve as trustees.
F7 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.79, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.